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The relevance of cancer to human health is extremely high
and the efforts to understand and control the processes
related to the oncogenic modifications that take place in cells
have increased, dramatically, in the past few decades [1–3].
The special issue presents a broad view of this subject.
Actually, oncogenic process was discussed by the authors
that contributed to the Special Issue and have clearly demon-
strated that this process involves the action of different agents
on the cell [1, 4–7].
The major contribution achieved was the diversity of
the approaches; the studies have brought together important
aspects of cell transformation and also concerted efforts
directed towards therapeutic procedures. The editors hope
that this issue can help partially to the complex problems
involved in these processes.
When we consider the etiology of tumor cells, papil-
lomaviruses come immediately to mind: the relevance of
HPVs (human papillomavirus) in female cervical cancer has
obtained the priority in the virus-cancer relationship discus-
sion [1, 2, 4, 8–10]. Its incidence turns it in aworldwide human
health problem. In this volume, we have the opportunity
to study persistence or clearance in HPV infection in order
to allow the identification of risk groups, cofactors, and
strategies for prevention of cervical cancer. At the same time,
the issue presents results of research on less common HPV
types that might be involved in cervical lesions and that some
of these variants can be found in B-cell and T-cell epitopes
[11–15].
Animal models have played a contributions to the under-
standing of oncogenic processes [5, 10, 16–26]. One of them
deserves special attention: Bovine papillomavirus. This group
of viruses is directly related to serious clinical consequences
in bovine, namely papillomatosis, esophagus tract carcinoma,
and urinary bladder carcinoma leading to animal death and
in equids, sarcoid tumours that presents similar results [10,
18, 27]. These diseases lead to dramatic economic hazards.
BPV animal model has been studied in several aspects, as
illustrated in the different papers included in this issue,
since many aspects of bovine papillomavirus infection and
pathogenesis remain still to be clarified [28].The oncogenesis
process is mainly associated with different viral oncoprotein
expressions, which are involved in cell transformation [7, 12,
19, 29].The accuracy of diagnostic processes and the distribu-
tion of the different viral types [14, 26, 30–32] indicate which
types and variants deserve the special attention [8, 9, 25,
33, 34]. The expression and characterization of recombinant
viral oncoproteins are required to obtain biotechnological
products as antibodies and potential vaccines [9, 15, 35–
37]. Further studies show association of oncoproteins and
cell compounds, as PDGF𝛽 receptor and their actions in
transformation of epithelial cell to mesenchymal cell as well
as epithelial carcinogenesis of the urinary bladder [17, 33, 38].
The oncoproteins also act on host cell chromatin, in epithelial
and blood cells [18, 23, 27, 39].The virusDNA sequences have
been described in semen, urine, and other non conventional
host cells [10, 17, 20, 21, 23, 29, 33]. However, the initial event
of the malign process remains not determined.
Chromosome aberrations can be detected in very diverse
neoplastic process; bovine leukemia virus (BLV) was inves-
tigated and reported presenting chromosome breakage in
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lymphocytes [16] and in the central nervous system (CNS) of
cattle with neurological syndrome. While in papillomavirus,
the chromosome aberrations occur at random, in tumor cells,
virus sequences can be integrated in specific sites or the
malign process can be related to products as in leukemia,
fusion protein RUNX1/ETO that is generated by the chromo-
somal translocation t(8; 21) [40–43].
The oncogenic process can have another trigger, not
specifically chromatin lesions. Gap junctions are communi-
cating junctions which are important for tissue homeostasis,
and their disruption is involved in carcinogenic process;
connexin 43 deficiency is a clear example [44–46]. Cell
surface proteins are related as targets for the beginning of
the cancer development and consequently for cancer therapy
or diagnosis [47–50]. These aspects have been well discussed
in oncogenic processes; the expression of different genes in
breast tumors, alternative TrkAIII splice variant expressed by
advanced stage human neuroblastomas (NBs).
In a final evaluation, the papers pointed very clearly the
complexity of the events leading to cancer. This complexity,
obviously, reaches the diagnosis and therapy possibilities. In
the ongoing studies, molecules are being analyzed to create
ways to interfere with the tumor cell. In the special issue, viral
oncoproteins were also considered through bioinformatics
approach.The volume includes a detailed review of a purified
peptide from South American rattle snake, a venom chemical
crotamine [51–53] that is being discussed as a vector to reach
the malign cell.
Our major aim in organizing this volume was to empha-
size that the first step in oncogenic process is until now under
discussion and therefore is the key for prophylaxis, diagnosis,
and therapy. An attractive possibility is that the key remains
in any alteration in the natural history of a cell; any cell,
as any organism, has beginning, development, ageing, and
death. When this route is modified, due to a large range of
events, this cell can follow a different way and compete with
its similar tissue cells, and, when this occurs in advantage,
tumor cells win and the cancer happens.
The special issue (oncogenic processes) is celebrating the
80th birthday of Prof Dr. Willy Bec¸ak, former Director
of Instituto Butantan and remarkable researcher in cancer
etiology studies and in the developing of vaccines.
We hope that this special issue (oncogenic processes)
can contribute to this scientific area, bringing to readers
accurate data and important discussions about this subject;
but, mainly, we hope that this special issue will initiate new
discussions relating to the elucidation of mechanisms and
oncogenic process.
Rita de Cassia Stocco
Franco Peppino Roperto
Lubna Nasir
Marcelo Palma Sircili
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